-
Listing
Connecting Europe's Fixed Income MarketsOne connected fixed income ecosystemLer maisSeamless listing, trading, clearing and settlement for fixed income
-
Trading
Connecting Europe's Fixed Income MarketsOne connected fixed income ecosystemLer mais
Seamless listing, trading, clearing and settlement for fixed income
-
Clearing
Connecting Europe's Fixed Income MarketsOne connected fixed income ecosystemLer mais
Seamless listing, trading, clearing and settlement for fixed income
-
CSD
European CSD modelBuilding the CSD of Choice in EuropeLer maisEuronext Securities is shaping the future of European capital markets by enhancing integration, connectivity, and innovation.
-
Technology
Euronext Technology SolutionsHigh-Frequency Trading Solution (HFTS)Ler maisThe new generation of high-frequency risk trading platforms, offering the highest performance with ultra-low latency and minimal jitter, all at a low total cost of ownership.
-
Data
-
Indices
Access the white paperNext generation of indicesLer maisThis white paper marks the second edition of Euronext’s Index Outlook series, a recurring publication designed to give investors deeper insight into our index innovation agenda and the structural forces shaping global markets.
-
About Euronext
Euronext strategic planInnovate for Growth 2027Ler maisShaping capital markets for future generations
Curetis listing anniversary
Curetis celebrates one year listed anniversary
Curetis (ticker symbol: CURE) celebrates its one-year listed anniversary at Euronext by sounding the gong. Oliver Schacht, CEO Curetis, visits Beursplein 5 and sounds the gong.
Founded in 2007, Curetis is a molecular diagnostics company which focuses on the development and commercialization of reliable, fast and cost-effective products for diagnosing severe infectious diseases.
Curetis is a molecular diagnostics company focusing on the detection of severe infectious disease in hospitalized patients. Its CE IVD marked Unyvero platform is marketed across Europe and has recently also successfully completed a US FDA trial for its LRT lower respiratory tract infection cartridge.
For more information: www.curetis.com